NCT02905266已完成3 期
Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Bristol-Myers Squibb24 个研究点 分布在 4 个国家目标入组 106 人开始时间: 2016年10月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 24
- 主要终点
- Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)
研究概览
简要总结
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and Females, ages 15 years ≥ of age (Except where local regulations and/or institutional policies do not allow for subjects < 18 years of age to participate)
- •Subjects must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma that is unresectable or metastatic
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Subjects have not been treated by systemic anticancer therapy for unresectable or metastatic melanoma
排除标准
- •Subjects with active brain metastases or leptomeningeal metastases
- •Subjects with ocular melanoma
- •Subjects with active, known or suspected autoimmune disease
- •Other protocol defined inclusion/exclusion criteria could apply
结局指标
主要结局
Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)
时间窗: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.
次要结局
- Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ(Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks))
- Geometric Mean Trough Concentration of Ipilimumab(From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.)
- Objective Response Rate (ORR)(Week 12 following randomization, every 8 weeks for the first 12 months and then every 12 weeks until disease progression (approximately 20 months))
- Progression Free Survival (PFS)(From the date of randomization to the first date of documented progression (approximately 26 months))
- Percentage of Participants Affected by All Causality Grade 3 - 5 AEs(From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months))
- Geometric Mean Concentration of Nivolumab at End of Infusion (EOI)(From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported)
- Geometric Mean Trough Concentration of Nivolumab(From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.)
- Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs(Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks))
- Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs(From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months))
- Geometric Mean Concentration of Ipilimumab at End of Infusion (EOI)(From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported.)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
3 期
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaMelanomaNCT02714218Bristol-Myers Squibb387
进行中（未招募）
3 期
Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant TherapyHead and Neck CancerNCT03700905Universitätsklinikum Hamburg-Eppendorf276
进行中（未招募）
2 期
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaStage III Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7NCT02339571National Cancer Institute (NCI)600
进行中（未招募）
3 期
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerRenal Cell CarcinomaNCT03873402Bristol-Myers Squibb437
进行中（未招募）
3 期
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersRecurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC v7NCT02785952SWOG Cancer Research Network275